[1] K. Lieb, M. C. Zanarini, C. Schmahl, M. M. Linehan, and M. Bohus, “Borderline personality disorder,” vol. 364, pp. 453–461, 2004.
[2] L. A. Clark, “Assessment and Diagnosis of Personality Disorder : Perennial Issues and an Emerging Reconceptualization,” 2007.
[3] S. N. Mullins-Sweatt, M. Edmundson, S. Sauer-Zavala, D. R. Lynam, J. D. Miller, and T. A. Widiger, “Five-factor measure of borderline personality traits,” J. Pers. Assess., 2012.
[4] D. B. Samuel and T. A. Widiger, “A meta-analytic review of the relationships between the five-factor model and DSM-IV-TR personality disorders: A facet level analysis,” Clinical Psychology Review. 2008.
[5] E. Ralevski et al., “Avoidant personality disorder and social phobia: distinct enough to be separate disorders?,” Acta Psychiatr. Scand., vol. 112, no. 3, pp. 208–14, Sep. 2005.
[6] N. Czajkowski et al., “A Twin Study of Normative Personality and DSM-IV Personality Disorder Criterion Counts: Evidence for Separate Genetic Influences,” Am. J. Psychiatry, vol. 175, no. 7, pp. 649–656, Mar. 2018.
[7] A. Amad, N. Ramoz, P. Thomas, R. Jardri, and P. Gorwood, “Genetics of borderline personality disorder: Systematic review and proposal of an integrative model,” Neuroscience and Biobehavioral Reviews. 2014.
[8] M. A. Distel et al., “Familial Resemblance of Borderline Personality Disorder Features : Genetic or Cultural Transmission ?,” vol. 4, no. 4, 2009.
[9] M. T. Lo et al., “Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders,” Nat. Genet., 2017.
[10] M. B. et First, R. L. Spitzer, M. Gibbon, and J. B. W. Williams, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. 2002.
[11] M. First, M. Gibbon, and R. Spitzer, “Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II).,” Am. Psychiatr. Press. Inc., 1997.
[12] C. Y. Valenzuela, “Human sociogenetics,” Biol. Res., 2011.
[13] Y. Lecrubier et al., “The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI,” Eur. Psychiatry, vol. 12, no. 5, pp. 224–231, 1997.
[14] D. Manga, F. Ramos, and C. Morán, “The Spanish Norms of the NEO Five-Factor Inventory : New Data and Analyses for its Improvement,” vol. 4, pp. 639–648, 2004.
[15] J. R. Wendland, B. J. Martin, M. R. Kruse, K.-P. Lesch, and D. L. Murphy, “Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531,” Mol. Psychiatry, vol. 11, no. 3, pp. 224–226, 2006.
[16] P. Costa and R. McCrae, Revised NEO Personality Inventory (NEO-PI-R) and NEO Five Factor Model (NEO-FFI) Professional manual. Spanish version, 2nd ed. Madrid: TEA Ediciones SA, 2002.
[17] F. Gressier, R. Calati, and A. Serretti, “5-HTTLPR and gender differences in affective disorders: A systematic review,” Journal of Affective Disorders. 2016.
[18] R. Calati, F. Gressier, M. Balestri, and A. Serretti, “Genetic modulation of borderline personality disorder: Systematic review and meta-analysis,” Journal of Psychiatric Research. 2013.
[19] A. Frustaci, G. Pozzi, F. Gianfagna, L. Manzoli, and S. Boccia, “Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism in anxiety disorders and anxiety-related personality traits,” Neuropsychobiology, 2008.
[20] K. Lehto, J. Mäestu, E. Kiive, T. Veidebaum, and J. Harro, “BDNF Val66Met genotype and neuroticism predict life stress: A longitudinal study from childhood to adulthood,” Eur. Neuropsychopharmacol., 2016.
[21] A. Terracciano et al., “BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism,” Neuropsychopharmacology, 2010.
[22] S. Wagner, Ö. Baskaya, N. Dahmen, K. Lieb, and A. Tadić, “Modulatory role of the brain-derived neurotrophic factor Val66Met polymorphism on the effects of serious life events on impulsive aggression in borderline personality disorder,” Genes, Brain Behav., vol. 9, no. 1, pp. 97–102, 2010.
[23] K. Bresin, M. Sima Finy, and E. Verona, “Childhood emotional environment and self-injurious behaviors: The moderating role of the BDNF Val66Met polymorphism,” J. Affect. Disord., 2013.
[24] N. Kourmouli, M. Samakouri, A. Mamatsiou, G. Trypsianis, M. Livaditis, and S. Veletza, “Effect of BDNF Val66Met and serotonin transporter 5-HTTLPR polymorphisms on psychopathological characteristics in a sample of university students,” Psychiatr. Genet., 2013.
[25] M. M. Perez-Rodriguez et al., “Brain-derived neurotrophic factor Val66Met genotype modulates amygdala habituation,” Psychiatry Res. - Neuroimaging, 2017.
[26] C. C. Conway, G. M. Slavich, and C. Hammen, “Dysfunctional Attitudes and Affective Responses to Daily Stressors: Separating Cognitive, Genetic, and Clinical Influences on Stress Reactivity,” Cognit. Ther. Res., 2015.
[27] G. M. Khandaker, R. M. Pearson, S. Zammit, G. Lewis, and P. B. Jones, “Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life,” JAMA Psychiatry, vol. 71, no. 10, pp. 1121–1128, 2014.
[28] N. M. et al., “Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways,” Nat. Genet., vol. 50, no. 7, pp. 920–927, 2018.
[29] B. C. Haberstick et al., “Population Frequencies of the Triallelic 5HTTLPR in Six Ethnicially Diverse Samples from North America, Southeast Asia, and Africa,” Calcif. Tissue Int., 2015.